S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Price:
104 000
KRW
-0.76%
Market Closed
Market Cap:
2.4T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Sam Chun Dang Pharm Co Ltd
104000
-800 (-0.76%)
| 52 Week Range |
62 400
214 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Sam Chun Dang Pharm Co Ltd
Balance Sheet
Balance Sheet Decomposition
Sam Chun Dang Pharm Co Ltd
Sam Chun Dang Pharm Co Ltd
| Current Assets | 239B |
| Cash & Short-Term Investments | 150B |
| Receivables | 36.8B |
| Other Current Assets | 52.2B |
| Non-Current Assets | 254.2B |
| Long-Term Investments | 30.5B |
| PP&E | 96.5B |
| Intangibles | 109.2B |
| Other Non-Current Assets | 18.1B |
| Current Liabilities | 58.3B |
| Accounts Payable | 4.6B |
| Accrued Liabilities | 10.9B |
| Short-Term Debt | 22.5B |
| Other Current Liabilities | 20.3B |
| Non-Current Liabilities | 159.5B |
| Long-Term Debt | 36.4B |
| Other Non-Current Liabilities | 123B |
Balance Sheet
Sam Chun Dang Pharm Co Ltd
Sam Chun Dang Pharm Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
33 089
|
34 862
|
48 622
|
61 907
|
51 471
|
60 273
|
58 935
|
2 028
|
14
|
40 427
|
|
| Cash |
694
|
314
|
653
|
792
|
858
|
82
|
53
|
28
|
14
|
37 427
|
|
| Cash Equivalents |
32 395
|
34 548
|
47 969
|
61 115
|
50 613
|
60 191
|
58 882
|
2 000
|
0
|
3 000
|
|
| Short-Term Investments |
9 769
|
13 236
|
9 571
|
7 370
|
30 578
|
39 436
|
38 031
|
47 912
|
64 148
|
52 317
|
|
| Total Receivables |
33 944
|
32 687
|
38 618
|
39 065
|
37 082
|
38 900
|
36 540
|
38 589
|
39 004
|
35 111
|
|
| Accounts Receivables |
28 121
|
27 404
|
31 175
|
31 654
|
30 684
|
30 248
|
26 979
|
32 194
|
35 461
|
31 080
|
|
| Other Receivables |
5 823
|
5 283
|
7 443
|
7 411
|
6 398
|
8 652
|
9 561
|
6 395
|
3 543
|
4 031
|
|
| Inventory |
16 974
|
17 738
|
19 171
|
21 849
|
22 430
|
23 035
|
25 336
|
27 908
|
31 913
|
35 263
|
|
| Other Current Assets |
396
|
423
|
622
|
1 018
|
711
|
848
|
7 685
|
5 398
|
584
|
788
|
|
| Total Current Assets |
94 172
|
98 946
|
116 603
|
131 208
|
142 272
|
162 493
|
166 528
|
168 920
|
157 749
|
163 906
|
|
| PP&E Net |
54 589
|
59 307
|
57 928
|
55 175
|
60 727
|
57 334
|
63 276
|
74 112
|
87 212
|
90 009
|
|
| PP&E Gross |
54 589
|
59 307
|
57 928
|
55 175
|
60 727
|
57 334
|
63 276
|
74 112
|
87 212
|
90 009
|
|
| Accumulated Depreciation |
28 889
|
26 640
|
29 867
|
35 657
|
41 235
|
46 724
|
46 898
|
52 158
|
58 835
|
66 596
|
|
| Intangible Assets |
3 125
|
4 822
|
9 321
|
11 290
|
17 312
|
26 480
|
29 124
|
44 685
|
77 095
|
92 556
|
|
| Goodwill |
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
1 000
|
0
|
0
|
38
|
2 961
|
4 723
|
|
| Long-Term Investments |
14 590
|
15 656
|
15 685
|
26 859
|
33 694
|
34 466
|
50 951
|
40 311
|
34 601
|
33 660
|
|
| Other Long-Term Assets |
2 270
|
1 785
|
1 831
|
1 867
|
2 409
|
5 632
|
3 455
|
14 186
|
9 430
|
19 423
|
|
| Other Assets |
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
3 745
|
|
| Total Assets |
172 491
N/A
|
184 260
+7%
|
205 113
+11%
|
230 143
+12%
|
261 158
+13%
|
290 151
+11%
|
317 079
+9%
|
345 997
+9%
|
372 793
+8%
|
408 022
+9%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
7 320
|
4 770
|
3 828
|
4 435
|
3 393
|
3 617
|
3 178
|
4 758
|
4 943
|
3 862
|
|
| Accrued Liabilities |
3 766
|
4 076
|
4 675
|
5 717
|
9 558
|
10 295
|
6 448
|
8 328
|
10 865
|
11 428
|
|
| Short-Term Debt |
3 434
|
4 631
|
6 979
|
2 336
|
2 212
|
2 439
|
2 011
|
1 580
|
2 756
|
12 226
|
|
| Current Portion of Long-Term Debt |
1 700
|
0
|
0
|
0
|
10 766
|
11 840
|
915
|
20 714
|
1 330
|
21 470
|
|
| Other Current Liabilities |
10 327
|
8 236
|
10 665
|
11 211
|
12 490
|
17 014
|
11 106
|
18 701
|
18 265
|
8 971
|
|
| Total Current Liabilities |
26 548
|
21 714
|
26 147
|
23 699
|
38 419
|
45 206
|
23 658
|
54 081
|
38 160
|
57 957
|
|
| Long-Term Debt |
0
|
0
|
0
|
3 000
|
7 177
|
9 573
|
24 149
|
29 248
|
72 505
|
19 929
|
|
| Deferred Income Tax |
1 081
|
666
|
310
|
1 753
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
34 236
|
39 998
|
45 837
|
52 417
|
57 245
|
65 325
|
71 070
|
76 206
|
71 901
|
77 961
|
|
| Other Liabilities |
5 186
|
7 565
|
7 654
|
7 934
|
9 799
|
12 175
|
11 576
|
12 367
|
16 487
|
31 676
|
|
| Total Liabilities |
67 050
N/A
|
69 944
+4%
|
79 947
+14%
|
88 804
+11%
|
112 640
+27%
|
132 279
+17%
|
130 453
-1%
|
171 902
+32%
|
199 052
+16%
|
187 523
-6%
|
|
| Equity | |||||||||||
| Common Stock |
10 526
|
10 619
|
11 000
|
11 053
|
11 053
|
11 053
|
11 384
|
11 384
|
11 384
|
11 729
|
|
| Retained Earnings |
80 797
|
89 093
|
97 175
|
106 081
|
120 001
|
128 793
|
126 987
|
112 514
|
112 079
|
106 015
|
|
| Additional Paid In Capital |
12 826
|
13 302
|
15 825
|
16 596
|
16 596
|
16 596
|
46 911
|
46 911
|
47 283
|
99 640
|
|
| Unrealized Security Profit/Loss |
65
|
78
|
59
|
6 385
|
356
|
206
|
223
|
1 937
|
1 378
|
1 451
|
|
| Treasury Stock |
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
1 988
|
|
| Other Equity |
3 213
|
3 213
|
3 213
|
3 213
|
3 213
|
3 213
|
3 109
|
3 336
|
3 606
|
3 651
|
|
| Total Equity |
105 440
N/A
|
114 317
+8%
|
125 166
+9%
|
141 339
+13%
|
148 518
+5%
|
157 872
+6%
|
186 626
+18%
|
174 095
-7%
|
173 741
0%
|
220 499
+27%
|
|
| Total Liabilities & Equity |
172 491
N/A
|
184 260
+7%
|
205 113
+11%
|
230 143
+12%
|
261 158
+13%
|
290 151
+11%
|
317 079
+9%
|
345 997
+9%
|
372 793
+8%
|
408 022
+9%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
20
|
21
|
21
|
21
|
21
|
21
|
22
|
22
|
22
|
23
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
